A Parliamentary Panel indicating to a collusive link between drug manufacturers, officials of Drugs Control Organisation and medical experts in allowing grants to new drugs, said that drugs banned, withdrawn or even discarded in developed nations are in circulation in India. This was shocking news to the entire country and a big question mark on drug manufacturers and Drugs Control Organisation in India.
The Parliamentary Standing Committee on Health and Family Welfare also pointed out to serious spaces and abnormalities on the supports of new drugs and indicated that about 33 such drugs were sanctioned minus steering clinical trials on Indian patients.
Worried at concerns of security of Indian patients consuming such new drugs approved by the Central Drugs Standard Control Organisation (CDSCO), the top body handling endorsement of drugs, the Committee apprehended "this matter requires being revised to guarantee security of patients, fair play, clearness and liability."
The Committee even mentioned that scrutiny of about 42 drugs picked up indiscriminately concerning endowment of drug approvals in absolute disrespect of supervisory processes and violation of rules and pointed out to approval files of 3 major controversial drugs namely; lomefloxacin, pefloxacin and sparfloxacin. These were found omitted and unnoticeable.
It has been proved that these drugs were never sold, endorsed or inhibited in developed countries like Canada, US, Britain, Australia and other countries. The Committee has even pointed to a close link between drug industry and medical professionals who give their judgement on "personal opinion" to drive "unsafe" drugs for usage.
The Committee held that it expresses its deep concern and intense displeasure at the state of affairs. It also indicated that the core duty of Ministry is to guarantee that the staff at CDSCO does not indulge in indiscretions while approving the process of latest drugs that can possibly have adversative impact on the lives of individuals.